A live transmission showcasing the first Made-in-India Shockwave MASON with a hybrid approach using Drug-Eluting Balloon (DEB) was presented to an audience at NIC 2025 in Mumbai.  This event, featuring Dr. Sarita Rao, marked a significant advancement in interventional cardiology and innovative treatment strategies within India. 
In a moment of immense pride and medical advancement, Dr. Sarita Rao, one of India’s leading cardiologists, recently demonstrated the first Made-in-India Shockwave MASON at the NIC 2025 conference in Mumbai. This historic live transmission not only celebrated a breakthrough in interventional cardiology but also underscored India’s growing leadership in global medical innovation. Dr. Sarita Rao’s pivotal role in this event highlighted the country’s advancing capabilities in the field of cardiac care, and positioned the Shockwave MASON as a groundbreaking solution for heart disease treatment.

Dr. Sarita Rao: A Visionary in Cardiac Care

Dr. Sarita Rao is a trailblazer in interventional cardiology with a deep commitment to advancing heart disease treatment. As a renowned expert, she continuously integrates innovative technologies to improve patient outcomes. Her dedication to patient-centered care is evident in her leadership, not just within India but globally. Dr. Sarita Rao has been instrumental in shaping modern cardiac care through her expertise and passion for education, mentoring young cardiologists, and actively participating in international conferences. Her contributions continue to inspire and influence the field, making her a key figure in the future of cardiac health. Moreover Dr Sarita Rao’s expertise with the Shockwave MASON system, particularly its hybrid approach with Drug-Eluting Balloons (DEB), illustrated her unique ability to blend cutting-edge technology with patient-centered care. This hybrid method offers a powerful solution for patients suffering from calcified coronary artery disease, improving outcomes and reducing complications.

Introducing Shockwave MASON: A Game-Changing Technology in Heart Treatment

The live demonstration of the Shockwave MASON device at the NIC 2025 conference was a pivotal moment in showcasing India’s innovation in cardiac technology. Shockwave MASON is a breakthrough device designed for intravascular lithotripsy (IVL), a cutting-edge procedure that uses sonic pressure waves to break down calcified plaques in the coronary arteries. These calcified plaques can cause significant blockages, which traditional treatments like balloon angioplasty may struggle to address. The Shockwave MASON addresses these challenges with a unique ability to safely disrupt hard calcifications, without damaging the surrounding artery tissue.

This technology is a critical advancement, particularly for patients with heavily calcified coronary arteries, who often have limited treatment options. By targeting the calcified plaque specifically, Shockwave MASON reduces the risk of artery damage and minimizes complications, making it a safer and more effective solution for restoring blood flow in patients suffering from severe heart blockages.

The Impact of Shockwave MASON on Heart Treatment

The introduction of the Shockwave MASON device has profound implications for the treatment of heart blockages. Here are some of the key benefits:

1. Enhanced Effectiveness: The device delivers focused sonic pressure waves that break down calcified plaque, making plaque removal easier and stent placement more effective. This ultimately results in better blood flow restoration and improved outcomes for patients.
   
2. Improved Safety: Unlike traditional invasive procedures, Shockwave MASON is minimally invasive. It significantly reduces the risk of vessel injury, dissections, and restenosis (re-narrowing of the artery), making it a safer option for patients, particularly those with severe calcification.
   
3. Faster Recovery: As a minimally invasive procedure, Shockwave MASON is typically performed as an outpatient procedure, allowing patients to return home the same day. This means shorter recovery times and less discomfort compared to traditional procedures like angioplasty, allowing patients to get back to their normal activities more quickly.

In Which Diseases Is Shockwave MASON Used in Heart Treatment?

Shockwave MASON is primarily used for:

• Coronary Artery Disease with Calcified Lesions
  
• Complex Coronary Blockages Resistant to Normal Angioplasty
  
• Re-treatment in Previously Failed Angioplasty Cases
  
  

A Proud Moment for India’s Healthcare

The live transmission of the Shockwave MASON at NIC 2025, led by Dr. Sarita Rao, marks a historic and proud moment for Indian cardiology. This achievement underscores the growing role of India in healthcare innovation and highlights the country’s potential to offer affordable, effective solutions to global healthcare challenges. As one of the best cardiologist in Indore, Dr. Sarita Rao continues to push the boundaries of cardiac care, and this milestone stands as a testament to her leadership and vision. As India continues to lead in innovative healthcare solutions, we can look forward to even more groundbreaking moments that will shape the future of heart disease treatment.